Google DeepMind spinoff Isomorphic Labs expects testing on its first AI-designed drugs to begin this year, as tech startups race to turn algorithmic magic into actual treatments. “We’ll hopefully have some AI-designed drugs in clinical trials by the end of the year,” the firm’s Nobel Prize-winning CEO Demis Hassabis told a panel at the World Economic Forum in Davos this week.